Search ASX code:
Generic filters

Search ASX code:
Generic filters

Search ASX code:
Generic filters

Want to invest ethically for a brighter future?
(but still make lots of money)?

Want to invest ethically for a brighter future? (but still make lots of money)?

 Take Rask’s FREE Ethical Investing course today.

  • Online & 100% free
  • ETFs, shares & Super
Want to invest ethically for a brighter future? 
(but still make lots of money)?

 Take Rask’s FREE online Ethical Investing course.

CSL (ASX:CSL) cancels UQ COVID vaccine trial

CSL Limited (ASX: CSL) announced some disappointing UQ COVID-19 vaccine news today.

Here’s what happened

CSL said that the University of Queensland (UQ) announced today its phase 1 trial of its COVID-19 vaccine showed that it elicited a robust response towards the virus and has a strong safety profile with no serious adverse events or safety concerns in 216 trial participants.

However, whilst CSL and UQ were working towards phases 2 and 3 of a clinical trial and large scale manufacture of the vaccine upon successful completion of the trials, there was a major setback revealed in the first phase of the trial.

The phase 1 data showed the generation of antibodies directed towards the molecular clamp component of the vaccine. These antibodies interfere with certain HIV diagnostic tests. The potential for this cross-reaction had been anticipated before the trial commenced and participants were informed this could occur.

Blood tests showed that these molecular clamp antibodies did cause a false positive on a range of HIV tests. Follow up tests confirmed there is no HIV virus present, just the false positive. CSL confirmed there is no possibility the vaccine causes infection.

With advice from experts, CSL and UEQ have worked through the implications of this rolling out to the broad population. It is generally agreed that significant changes would be needed to well-established HIV testing to accommodate the rollout of this vaccine.

Therefore, CSL and the Australian Government have agreement vaccine development will not proceed to the next phase of the trial.

The phase 1 trial will continue to see how long the antibodies persist. Studies so far are showing that levels are already falling.

UQ vaccine co-lead, Professor Paul Young, said that although it was possible to re-engineer the vaccine, the team did not have the luxury of time needed: “Doing so would set back development by another 12 or so months, and while this is a tough decision to take, the urgent need for a vaccine has to be everyone’s priority.”

Summary thoughts

It’s disappointing that there won’t be an ‘Australian-made’ vaccine available. But the public need to have confidence in what’s distributed nationally.

CSL is currently working on manufacturing 30 million doses of the Oxford-Astrazeneca vaccine and with the first doses planned for release early next year. CSL has agreed to manufacture another 20 million doses.

CSL doesn’t expect this will impact previous FY21 guidance.

There are a few other vaccine candidates which can seemingly provide the protection society needs. This doesn’t change my investment thoughts, I still think a business like Pushpay Holdings Ltd (ASX: PPH) looks attractive for the long term at this price.

Is BNPL the opportunity of a lifetime or is the sector a ticking time bomb?

Rask's analyst has just finished a 7,500-word report, The Ultimate BNPL Sector Report, taking a deep dive into this booming ASX sector. It shines a spotlight on each of the major players. You can get the full analyst report for FREE by CLICKING HERE NOW or entering your email below.

Note: the report is 100% free.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Afterpay, Zip Co, Sezzle…

Is BNPL the opportunity of a lifetime or is the sector a ticking time bomb?

Rask's analyst has just finished a 7,500-word report, The Ultimate BNPL Sector Report, taking a deep dive into this booming ASX sector. It shines a spotlight on each of the major players. You can get the full analyst report for FREE by CLICKING HERE NOW.

Note: the report is 100% free.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

Keep reading:

Rask Media’s Ultimate BNPL Sector Report

Afterpay, Zip, Sezzle… is this the opportunity of a lifetime? Or is BNPL a ticking time bomb? This 7,500-word analyst report takes a deep dive into the BNPL sector and shines a spotlight on each of the major players in this booming market. 

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

As we emerge from COVID-19, some tech companies are growing faster than ever. Rask’s investment analysts have identified 3 growth stocks set to benefit. Big time.

Enter your email below to access this report for free, including the names, ticker codes and analysis.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.